Daily Cardiology Research Analysis
Analyzed 41 papers and selected 3 impactful papers.
Summary
Today’s top cardiology papers span clinical outcomes, population genomics, and systems metabolomics. Long-term data show that patients with coexisting aortic stenosis and transthyretin cardiac amyloidosis face higher all-cause mortality and heart failure hospitalization rates after TAVR referral. A multi-ancestry GWAS incorporating gene–depressive symptom interactions identified novel blood pressure loci and druggable targets, while large-scale metabolomics mapped 270 fibrinogen-associated metabolites linking coagulation, inflammation, and vascular risk.
Research Themes
- Amyloid cardiomyopathy complicating aortic stenosis and long-term outcomes
- Gene–environment interactions linking mood disturbance and hypertension biology
- Metabolomic signatures of coagulation and vascular inflammation
Selected Articles
1. Long-term outcomes in patients with aortic stenosis and transthyretin cardiac amyloidosis.
In a prospective, multicenter cohort of severe AS patients referred for TAVR, those with transthyretin amyloidosis had significantly higher long-term all-cause mortality and higher rates of heart failure hospitalization compared with lone AS. These findings extend prior 1-year observations and underscore the need to detect CA and to evaluate CA-specific therapies in the AS population.
Impact: Provides robust, adjusted long-term outcome data in a common but under-recognized AS phenotype, informing risk stratification and potential therapeutic trials.
Clinical Implications: Screening for transthyretin amyloidosis using bone scintigraphy in elderly severe AS candidates for TAVR may refine prognosis and guide consideration of amyloid-directed therapies and closer post-TAVR heart failure surveillance.
Key Findings
- Among 406 severe AS patients, 11.6% had transthyretin cardiac amyloidosis confirmed by bone scintigraphy.
- AS-CA was associated with higher all-cause mortality over 5.4 years (adjusted HR 1.72, 95% CI 1.22–2.42; p=0.002).
- Heart failure hospitalization rate was nearly doubled in AS-CA vs lone AS (129 vs 65 per 1000 patient-years; p=0.022), despite no difference in CV mortality or time to first HHF.
Methodological Strengths
- Prospective, multicenter, observational case-control design with standardized bone scintigraphy to phenotype amyloidosis.
- Robust multivariable adjustment including EuroSCORE-II and valve replacement status; long median follow-up (~5.4 years).
Limitations
- Observational design cannot exclude residual confounding and selection biases inherent to TAVR referral populations.
- No demonstrated difference in cardiovascular mortality; mechanisms for higher all-cause mortality require elucidation.
Future Directions: Randomized or pragmatic trials testing transthyretin amyloidosis-directed therapies in AS-CA, and integrative risk models incorporating scintigraphy and biomarkers to guide management pre- and post-TAVR.
BACKGROUND: The coexistence of aortic stenosis (AS) and transthyretin cardiac amyloidosis (CA) is common. If treated with transcatheter aortic valve replacement (TAVR), patients with the combined phenotype (AS-CA) have a similar survival at 1 year compared to those with lone AS. This study aims to evaluate the long-term outcomes of AS-CA compared to lone AS. METHODS: Using a prospective, multicenter, observational, case-control design, we studied patients with severe AS referred for TAVR. All underwent bone scintigraphy to differentiate between AS-CA and lone AS. Outcomes were compared between the two cohorts. Mortality (all-cause and cardiovascular [CV]) and hospitalization for heart failure (HHF) were captured as clinical endpoints for long-term outcome. RESULTS: 406 patients [84(80-88) years, 50 % female, EuroSCORE-II 4.2 (3.7-5.0)] were recruited, of which 47 (11.6 %) had AS-CA (all transthyretin). Over a follow-up of 5.4 (4.9-5.8) years, 244 (60.1 %) patients died. AS-CA was associated with higher all-cause mortality (crude HR 1.75, 95 % CI 1.24-2.46; log-rank, p = 0.001), which remained significant after multivariate adjustment for clinical confounders (EuroSCORE-II, valve replacement; adjusted HR 1.72, 95 % CI 1.22-2.42; p = 0.002). AS-CA was not associated with CV mortality (log-rank, p = 0.18) or time to first HHF (log-rank, p = 0.43), but the rate of HHF was significantly higher in AS-CA compared to lone AS (129 versus 65 per 1000 patient years, p = 0.022). CONCLUSION: AS-CA is associated with an increased long-term risk of all-cause mortality and rate of hospitalization for heart failure compared to patients with AS. Further studies evaluating the role of CA-specific therapies are warranted in this population.
2. A Large-Scale Genome-wide Association Study of Blood Pressure Accounting for Gene-Depressive Symptomatology Interactions in 564,680 Individuals from Diverse Populations.
This multi-ancestry GWAS meta-analysis incorporating gene-by-depressive symptom interactions identified 16 BP loci with interaction signals, 11 from non-European populations, and prioritized 36 genes and 11 druggable targets. Results link mood disturbance biology with BP regulation and open avenues for repurposing antihypertensives and targeting neurocardiometabolic pathways.
Impact: Demonstrates the value of incorporating mental health context into cardiometabolic genetics, revealing novel BP loci and therapeutic targets particularly relevant to underrepresented populations.
Clinical Implications: While not immediately practice-changing, findings support risk stratification and prevention strategies in individuals with depressive symptoms and suggest drug repurposing targets integrating neuropsychiatric and antihypertensive pathways.
Key Findings
- Identified 7 novel BP loci showing gene-by-depressive symptom interaction and interaction signals at 9 known BP loci (total 16 loci).
- Eleven of the 16 interaction loci were derived from non-European populations, underscoring the value of diversity.
- Post-GWAS prioritization yielded 36 genes and 11 druggable targets linked to synaptic and neuronal signaling and known antihypertensive pathways.
Methodological Strengths
- Very large multi-ancestry sample (n=564,680) across 67 cohorts with explicit gene-by-environment interaction modeling.
- Comprehensive post-GWAS prioritization and integrative druggability analyses to map biological pathways and therapeutic targets.
Limitations
- Heterogeneity in depressive symptom assessment across cohorts and potential residual confounding in interaction analyses.
- Predominance of European ancestry (85%) despite diverse inclusion; replication of interaction effects remains challenging.
Future Directions: Prospective studies integrating standardized psychiatric phenotyping with ambulatory BP monitoring and functional work to validate mechanisms and test precision prevention or drug repurposing strategies.
Gene-environment interactions may enhance our understanding of blood pressure (BP) biology. We conducted a meta-analysis of multi-population genome-wide association studies of BP traits accounting for gene-depressive symptomatology (DEPR) interactions. Our study included 564,680 adults from 67 cohorts and 4 population backgrounds (African (5%), Asian (7%), European (85%), and Hispanic (3%)). We discovered seven previously unreported BP loci showing gene-DEPR interaction. These loci mapped to genes implicated in neurogenesis (TGFA, CASP3), lipid metabolism (ACSL1), neuronal apoptosis (CASP3), and synaptic activity (CNTN6, DBI). We also showed evidence for gene-DEPR interaction at nine known BP loci, further suggesting links between mood disturbance and BP regulation. Of the 16 identified loci, 11 loci were derived from non-European populations. Post-GWAS analyses prioritized 36 genes, including genes involved in synaptic functions (DOCK4, MAGI2) and neuronal signaling (CCK, UGDH, SLC01A2). Integrative druggability analyses identified 11 druggable candidate gene targets linked to pathways involved in mood disorders as well as known antihypertensive drugs. Our findings emphasize the importance of considering gene-DEPR interactions on BP, particularly in non-European populations. Our prioritized genes and druggable targets highlight biological pathways connecting mood disorders and hypertension and suggest opportunities for BP drug repurposing and risk factor prevention, especially in individuals with DEPR.
3. Fibrinogen-Associated Plasma Metabolites and Implications for Coagulation, Inflammation, and Vascular Diseases.
Across 10,533 participants and two metabolomics platforms, 270 plasma metabolites were significantly associated with fibrinogen after covariate adjustment, prominently involving lipid classes and hormone-related metabolites. The findings map endogenous, exogenous, and microbiome-linked pathways connecting coagulation and inflammation with vascular risk beyond previously cataloged CVD associations.
Impact: Provides a comprehensive metabolomic atlas linking fibrinogen to lipids, hormones, and microbial co-metabolites, generating mechanistic hypotheses for coagulation–inflammation–vascular risk pathways and novel biomarker discovery.
Clinical Implications: These metabolite associations may inform risk stratification and therapeutic targeting of thrombo-inflammatory pathways, motivating validation for prognostic biomarkers and modifiable lifestyle or microbiome interventions.
Key Findings
- Across six U.S. cohorts (n=10,533), 270 of 789 metabolites were significantly associated with plasma fibrinogen (FDR < 0.05).
- Associated metabolites were enriched for glycerophospholipids, sphingolipids, and fatty acyls; associations partly persisted after CRP adjustment, implicating nonredundant biology.
- Serotonin, thyroxine, sex-hormone derivatives, exogenous compounds, and microbial co-metabolites were linked to fibrinogen, suggesting endogenous, lifestyle, and microbiome influences.
Methodological Strengths
- Large multi-cohort design with two independent metabolomics platforms (Broad and Metabolon) and rigorous FDR control.
- Extensive covariate adjustment including lipoprotein levels and sensitivity analyses with CRP.
Limitations
- Cross-sectional design precludes causal inference and may be susceptible to reverse causation.
- Platform and cohort heterogeneity may contribute to measurement variability; generalizability beyond U.S. cohorts requires study.
Future Directions: Prospective validation linking fibrinogen-associated metabolites to incident thrombotic and cardiovascular events, and interventional studies modulating candidate pathways (e.g., lipid subclasses, microbiome) to reduce vascular risk.
BACKGROUND: Fibrinogen is a critical coagulation factor that plays an essential role in thrombosis and is elevated in individuals with chronic inflammation. Here, we used fibrinogen as a representative quantitative measure of pro-coagulant risk and evaluated metabolites associated with fibrinogen levels through non-targeted plasma metabolomic profiling (Broad and Metabolon platforms). METHODS: Our analysis included 10,533 individuals across six U.S. based cohorts representing diverse population groups. The cross-sectional relationship between each of 789 tested metabolites and plasma fibrinogen concentration was assessed with adjustment for relevant covariates such as age, sex, body mass index, and circulating lipoprotein levels. RESULTS: Meta-analysis of per-cohort results revealed 270 metabolites significantly associated with fibrinogen level (FDR adjusted p-value < 0.05). Lipid species such as glycerophospholipids, sphingolipids, and fatty acyls were prevalent among significantly associated metabolites; some of these may capture effects of inflammation, as supported by sensitivity analyses adjusted for C-reactive protein. Significant associations between fibrinogen levels and serotonin, thyroxine, and sex-hormone derivatives may capture endogenous influences on fibrinogen levels. Exogenous compounds and microbial co-metabolites significantly associated with fibrinogen also implicate lifestyle and microbiome risk-factors. Only a portion of fibrinogen-associated metabolites (30%) have been associated with a cardiovascular disease outcome in a prior study, suggesting the associations discovered here may provide insights on vascular biology which case-control studies may not yet be powered to detect. CONCLUSIONS: These findings contribute to a growing list of metabolite biomarkers that may influence coagulation and inflammation pathways and may thereby contribute to vascular risk.